Immutep Limited Forecasted to Earn FY2029 Earnings of $0.27 Per Share (NASDAQ:IMMP)

Immutep Limited (NASDAQ:IMMP) – Investment analysts at Capital One Financial issued their FY2029 earnings per share (EPS) estimates for Immutep in a research report issued on Tuesday, July 16th. Capital One Financial analyst N. Quibria anticipates that the biotechnology company will post earnings per share of $0.27 for the year. Capital One Financial currently has a “Overweight” rating and a $10.00 price target on the stock. The consensus estimate for Immutep’s current full-year earnings is ($0.28) per share.

Separately, Robert W. Baird decreased their price target on Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, June 27th.

Immutep Stock Down 1.5 %

IMMP opened at $2.00 on Thursday. The business’s fifty day simple moving average is $2.57 and its 200 day simple moving average is $2.48. Immutep has a 52 week low of $1.58 and a 52 week high of $3.34.

Hedge Funds Weigh In On Immutep

Several hedge funds and other institutional investors have recently modified their holdings of IMMP. BNP Paribas Financial Markets lifted its stake in shares of Immutep by 15.4% in the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 4,700 shares in the last quarter. Virtu Financial LLC raised its holdings in shares of Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 32,864 shares during the period. PFG Investments LLC purchased a new stake in shares of Immutep during the 1st quarter valued at about $119,000. Meridian Wealth Management LLC raised its holdings in shares of Immutep by 3.6% during the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 11,250 shares during the period. Finally, Oracle Investment Management Inc. raised its holdings in shares of Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after buying an additional 48,449 shares during the period. 2.32% of the stock is owned by institutional investors and hedge funds.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.